All In Biotech

Drug Trial Radar · NCT07148128

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of WEF-001 in Participants With Advanced KRAS- Mutant Solid Tumours.

Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Jul 28, 2025

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
Auricula Biosciences Inc.Industry
Sponsor type
Industry
Collaborators
Simbec-Orion Group
First posted
Aug 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.

Conditions

  • Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma
  • Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
  • Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer
  • Advanced Solid Tumors
  • Advanced or Metastatic KRAS-mutant Tumor

Interventions

  • WEF-001Drug

    Starting dose of 0.3 mg/m2 q4wks IV, dose escalation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: To characterize the safety and tolerability profiles of WEF-001 administered as monotherapy.Time frame: Through study completion, an average of 1 year.
  2. Phase 2: To evaluate the antitumour activity following WEF-001 administration as monotherapy.Time frame: Trough study completion, an average of 2 years.

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • NEXT Oncology Dallas

    Dallas, Texas · Recruiting

  • Next Oncology, San Antonio

    San Antonio, Texas · Recruiting

  • Princess Margareth Cancer Center

    Toronto, Ontario, Canada · Recruiting

  • Oxford University Hospital

    Headington, Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.